Citations

Clear

4847 citation(s) found for "Yu, Eric".

Experience with Telemedicine in a Tertiary Academic Otologic Clinic During the COVID-19 Pandemic
Xie, Katherine , Gottlich, Harrison C., Yeakel, Sarah, Nassiri, Ashley M. , Moore, Eric J. , Carlson, Matthew L. , Xie, Katherine Z , Antezana, Luis A.

Mayo Clinic

Otology & Neurotology | December 12, 2022 | Volume: 44 | Issue: 1 | Pages: 72-80

10.1097/mao.0000000000003755 | PMID 36509445 Get It

Objective To examine the utility of telemedicine in a tertiary otologic practice. Study Design Retrospective case series. Setting Tertiary neurotology clinic. Patients Consecutive adult patients presenting via video visit between January 2020 and January 2021. Intervention(s) Televideo modality to conduct visits with patients seeking evaluation for new concerns, second opinions, or routine follow-up for established conditions. Main Outcome Measure(s) Success of the televideo visit defined by the televideo visit being sufficient for determining a definitive plan and not requiring deferment of recommendations for a subsequent in-person visit. Results A total of 102 televideo visits were performed among 100 unique patients. Of those, 92 (90.2%) visits were for second opinions or evaluation of new concerns, most commonly for vestibular schwannoma (n = 32, 31.4%), followed by sensorineural hearing loss (n = 20, 19.6%). Other visits were conducted for early postoperative follow-up and established general follow-up. In 91.2% of cases (n = 93), patients were successfully evaluated and provided recommendations from the initial video visit. All visits with patients having a diagnosis of meningioma (n = 7), and nearly all with vestibular Schwannoma (97%, n = 31) and sensorineural hearing loss (95%, n = 19) were successful. Of the 79 patients offered surgery as one potential treatment option, 31 patients underwent surgery at our institution by time of review. Patients with unsuccessful visits (n = 9, 8.8%) were advised to schedule additional in-person diagnostic imaging, vestibular testing, or cochlear implant candidacy evaluation to establish a more definitive care plan. Conclusion Virtual televideo visits were successful for a high percentage of selected patients seen at a tertiary neurotology practice, particularly those seeking evaluation of vestibular schwannoma or sensorineural hearing loss.
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium
Rodday, Angie Mae , Parsons, Susan K. , Upshaw, Jenica , Friedberg, Jonathan W. , Gallamini, Andrea , Hawkes, Eliza A. , Hodgson, David , Johnson, Peter , Link, Brian K. , Mou, Eric , Evens, Andrew M. , Upshaw, Jenica N , Hawkes, Eliza , Savage, Kerry J , Zinzani, Pier Luigi , Maurer, Matthew , Evens, Andrew M , Link, Brian K , Gallamini, Andrea , Hodgson, David , Johnson, Peter , K Parsons, Susan , Mou, Eric , Savage, Kerry J. , Zinzani, Pier Luigi , Maurer, Matthew J.

Mayo Clinic

Journal of Clinical Oncology | December 10, 2022 | Volume: 41 | Issue: 11 | Pages: 2076-2086

10.1200/jco.22.02473 | PMID 36495588 Get It

PURPOSE The International Prognostic Score (IPS) has been used in classic Hodgkin lymphoma (cHL) for 25 years. However, analyses have documented suboptimal performance of the IPS among contemporarily treated patients. Harnessing multisource individual patient data from the Hodgkin Lymphoma International Study for Individual Care consortium, we developed and validated a modern clinical prediction model. METHODS Model development via Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis guidelines was performed on 4,022 patients with newly diagnosed advanced-stage adult cHL from eight international phase III clinical trials, conducted from 1996 to 2014. External validation was performed on 1,431 contemporaneously treated patients from four real-world cHL registries. To consider association over a full range of continuous variables, we evaluated piecewise linear splines for potential nonlinear relationships. Five-year progression-free survival (PFS) and overall survival (OS) were estimated using Cox proportional hazard models. RESULTS The median age in the development cohort was 33 (18-65) years; nodular sclerosis was the most common histology. Kaplan-Meier estimators were 0.77 for 5-year PFS and 0.92 for 5-year OS. Significant predictor variables included age, sex, stage, bulk, absolute lymphocyte count, hemoglobin, and albumin, with slight variation for PFS versus OS. Moreover, age and absolute lymphocyte count yielded nonlinear relationships with outcomes. Optimism-corrected c-statistics in the development model for 5-year PFS and OS were 0.590 and 0.720, respectively. There was good discrimination and calibration in external validation and consistent performance in internal-external validation. Compared with the IPS, there was superior discrimination for OS and enhanced calibration for PFS and OS. CONCLUSION We rigorously developed and externally validated a clinical prediction model in > 5,000 patients with advanced-stage cHL. Furthermore, we identified several novel nonlinear relationships and improved the prediction of patient outcomes. An online calculator was created for individualized point-of-care use.
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Francis, Prudence A. , Fleming, Gini F. , Láng, István, Ciruelos, Eva , Bonnefoi, Hervé , Bellet, Meritxell , Bernardo, Antônio , Climent, Miguel Ángel, Martino, Silvana, Bermejo, Begoña , Burstein, Harold J. , Davidson, Nancy E. , Walley, Barbara , Coleman, Robert E. , Müller, Bettina , Du, Fanny Le , Loibl, Sibylle , Ruepp, Barbara , Loi, Sherene , Coates, Alan S. , Gelber, Richard D. , Goldhirsch, Aron, Regan, Meredith M. , Ciruelos, Eva M , Bonnefoi, Hervé R , Walley, Barbara A , Ingle, J , Coleman, Robert E , Müller, Bettina , Le Du, Fanny , Loibl, Sibylle , Winer, Eric , Loi, Sherene , Colleoni, Marco , Coates, Alan S , Gelber, Richard D , Regan, Meredith M , Fleming, Gini , Francis, Prudence A , Geyer, Charles E. , Ingle, James N. , Winer, Eric P. , Colleoni, Marco

Mayo Clinic

Journal of Clinical Oncology | December 9, 2022 | Volume: 41 | Issue: 7 | Pages: 1370-1375

10.1200/jco.22.01065 | PMID 36493334 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The Suppression of Ovarian Function Trial (SOFT; ClinicalTrials.gov identifier: NCT00066690 ) randomly assigned premenopausal women with hormone receptor–positive breast cancer to 5 years of adjuvant tamoxifen, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. The primary analysis compared disease-free survival (DFS) between tamoxifen plus OFS versus tamoxifen alone; exemestane plus OFS versus tamoxifen was a secondary objective. After 8 years, SOFT reported a significant reduction in recurrence and improved overall survival (OS) with adjuvant tamoxifen plus OFS versus tamoxifen alone. Here, we report outcomes after median follow-up of 12 years. DFS remained significantly improved with tamoxifen plus OFS versus tamoxifen (hazard ratio, 0.82; 95% CI, 0.69 to 0.98) with a 12-year DFS of 71.9% with tamoxifen, 76.1% with tamoxifen plus OFS, and 79.0% with exemestane plus OFS. OS was improved with tamoxifen plus OFS versus tamoxifen (hazard ratio, 0.78; 95% CI, 0.60 to 1.01) and was 86.8% with tamoxifen, 89.0% with tamoxifen plus OFS, and 89.4% with exemestane plus OFS at 12 years. Among those who received prior chemotherapy for human epidermal growth factor receptor-2–negative tumors, OS was 78.8% with tamoxifen, 81.1% with tamoxifen plus OFS, and 84.4% with exemestane plus OFS. In conclusion, after 12 years, there remains a benefit from including OFS in adjuvant endocrine therapy, with an absolute improvement in OS more apparent with higher baseline risk of recurrence. [Media: see text]
Incidence of and Neurodevelopmental Outcomes After Late-Onset Meningitis Among Children Born Extremely Preterm
Bell, Edward F. , Barbara, T. , Greenberg, Rachel G. , Stoll, Barbara J. , DeMauro, Sara B. , Harmon, Heidi M. , Hintz, Susan R. , Das, Abhik , Puopolo, Karen M. , Bailey, Kirstin J., Biasini, Fred J., Chopko, Stephanie A., Collins, Monica V., Cosby, Shirley S., Johnston, Kristen C. , Moses, Mary Beth, Nelson, Kathleen G., Patterson, Cryshelle S., Peralta-Carcelén, Myriam , Phillips, Vivien A., Preskitt, Julie , Rector, Richard V., Whitley, Sally, Alksninis, Barbara, Bishop, Carmena, Burke, Robert T., Caskey, Melinda, Hensman, Angelita M. , Hoffman, Laurie , Johnson, Katharine, Keszler, Mary Lenore, Knoll, Andrea M., Lamberson, Vita, Laptook, Abbot R. , Leach, Theresa M., Little, Emilee, McGowan, Elizabeth C., Pierre, Lucille St., Stephens, Bonnie E., Ventura, Suzy, Vieira, Elisa , Vohr, Betty R. , Coleman, Kelly R., Guilford, Stephanie , Hartley-McAndrew, Michelle, Li, Emily, Reynolds, Anne Marie , Sacilowski, Michael G., Williams, Ashley, Zorn, William, Bhola, Monika , Fanaroff, Avroy A., Friedman, Harriet, Newman, Nancy S., Siner, Bonnie S., Walsh, Michele C. , Wilson-Costello, Deanne E. , Yalcinkaya, Gulgun, Caplan, Michael S. , Beiersdorfer, Traci , Bridges, Kate, Cahill, Tanya E., Donovan, Edward F., Dudley, Juanita , Fischer, Estelle E., Gratton, Teresa L., Grisby, Cathy, Hayes, Devan, Hessling, Jody, Jackson, Lenora, Kallapur, Suhas G. , Kirker, Kristin, Merhar, Stephanie L. , Mincey, Holly L., Muthig, Greg, Poindexter, Brenda B. , Schibler, Kurt, Stacey, Sara, Steichen, Jean J., Tepe, Stacey, Thompson, Julia, Mersmann, Marcia Worley, Wuertz, Sandra, Polin, Richard A. , Adams, Sally S., Leon, Maria Magdalena, Eubanks, Frances, Guzman, Alicia, Hensley, Gaynelle, Heyne, Elizabeth T., Heyne, Roy J. , Hickman, Jackie F., Lee, Lizette E. , Leps, Melissa H., Madden, Linda A., McDougald, E. Rebecca, Miller, Nancy A., Morgan, Janet S., Pavageau, Lara, Salhab, Walid A., Sepulveda, Pollieanna , Boatman, Catherine Twell, Vasil, Diana M., Waterbury, Jillian, Wyckoff, Myra H. , Ashley, Patricia L., Auten, Kathy J., Cotten, C. Michael , Finkle, Joanne, Fisher, Kimberley A. , Goldberg, Ronald N., Goldstein, Ricki F., Grimes, Sandra, Gustafson, Kathryn E. , Lohmeyer, Melody B., Malcolm, William , Adams‐Chapman, Ira , Blackwelder, Ann M., Bottcher, Diane I., Carlton, David P., Carter, Sheena L., Hale, Ellen C., Kendrick-Allwood, Salathiel, Laursen, Judith, Loggins, Yvonne, Mackie, Colleen, LaRossa, Maureen Mulligan, Sanders, Amy , Seabrook, Irma, Smikle, Gloria V., Wineski, Lynn, Akpa, Esther, Alaniz, Nora I., Allain, Elizabeth, Arldt-McAlister, Julie, Bradt, Pamela J., Burson, Katrina, Dieterich, Susan, Duncan, Andrea F. , Eason, Elizabeth, Evans, Patricia W., Harris, Beverly Foley, Franco, Claudia I., Garcia, Carmen, Hall, Donna J., Jiménez, Margarita, John, Janice , Jones, Patrick M., Kennedy, Kathleen A. , Siddiki, Saba Khan, Lillie, Layne M., Major-Kincade, Terri L., Martin, Sara C., McDavid, Georgia E., McKee, Shannon L. , Morris, Brenda H., Orekoya, Patricia Ann, Pedrozza, Claudia, Perez, Carrie M., Tate, Patti L. Pierce, Reddoch, Stacey, Rodgers, Shawna, Simmons, Maegan C., Sperry, Daniel K., Stephens, Emily K. , Tyson, Jon E., Whitely, Laura L., Wright, Sharon L., Dusick, Anna M., Gunn, Susan, Hamer, Faithe, Herron, Dianne E., Hines, Abbey C. , Joyce, Jeffery, Lemons, James A., Lytle, Carolyn, Miller, Lucy , Minnich, Heike M., Papile, L.A., Richard, Leslie, Smiley, Lucy, Sokol, Gregory M. , Wilson, Leslie Dawn, Acarregui, Michael J., Colaizy, Tarah T. , Eastman, Diane L., Goeke, Claire A., Johnson, Karen, Krutzfield, Nancy J., Schmelzel, Mendi L., Walker, Jacky R., Bass, Donia B., Ellsbury, Dan L., Tud, Tracy L., Bauer, Charles R., Duara, Shahnaz , Everett‐Thomas, Ruth , Fajardo-Hiriart, Sylvia, Eguaras, Silvia M. Frade, Garcia, Andrea, Berkovits, Michelle Harwood, Pierre, Helina, Riguard, Arielle, Stoerger, Alexandra, Gaetano, Lisa, Gauldin, Cheri, Holmes, Anne, Johnson, Kathy, Kilbride, Howard W. , Pallotto, Eugenia K. , Parimi, Prabhu S., Scott, Allison, Truog, William E., Besner, Gail E. , Clark, Erna, Gutentag, Julie, Jadcherla, Sudarshan R. , Luzader, Patricia, Park, Courtney, Shadd, Julie C., Stein, Melanie, Sullivan, Margaret, Bremer, Andrew A. , Higgins, Rosemary D. , Archer, Stephanie Wilson , Abbasi, Soraya, Bernbaum, Judy, Catts, Christine, Chaudhary, Aasma S. , Cucinotta, Dara M., Eichenwald, Eric C. , Gerdes, Marsha , Ghavam, Sarvin, Hurt, Hallam, Snyder, Jonathan, Vangala, Sarith, Ziolkowski, Kristina, Johnson, Julie Babish, Binion, Kyle, Bowman, Melissa, Burnell, Erica, D’Angio, Carl T., Fallone, Caitlin, Farooq, Osman , Guillet, Ronnie , Horihan, Cassandra A., Hunn, Julianne, Hust, Diane, Jensen, Rosemary L., Jones, Rachel , Kachelmeyer, Jennifer , Kushner, Emily, Maffett, Deanna, McKee, Kimberly G., Merzbach, Joan, Myers, Gary J. , Orme, Constance, Phelps, Dale L. , Dm, Prinzing, Reubens, Linda J., Rochez, Daisy, Rowan, Mary, Sabaratnam, Premini, Scorsone, Ann Marie, Wadkins, Holly I.M., Yost, Kelley, Zwetsch, Lauren, Gabrio, Jenna, Hastings, Betty K., LeBlond, David, Auman, Jeanette O’Donnell , Huitema, Carolyn M. Petrie , Poole, W. Kenneth, Wallace, Dennis, Zaterka-Baxter, Kristin M. , Baack, Michelle , Broadbent, Megan, Elenkiwich, Chelsey, Henning, Megan M., Hogden, Laurie A., Adams, Marian M. , Bahmani, Dona, Ball, M. Bethany , Bentley, Barbara, Bruno, Elizabeth F., Chock, Valerie Y. , Davis, Alexis S. , DeAnda, Maria Elena, DeBattista, Anne M., Earhart, Beth, Huffman, Lynne C. , Ismael, Magdy, Kohn, Jean G., Krueger, Casey E., Lee-Ancajas, Julie C., Lowe, Janice, Lucash, Ryan E., Palmquist, Andrew W., Patel, Jessica, Proud, Melinda S., Reichert, Elizabeth N., Sivakumar, Dharshi, John, Nicholas H. St., Stevenson, David K. , Meurs, Krisa P. Van , Wager, Natalie, Williams, R. Jordan , Weiss, Hali E., Brussa, Ana K. , Church, Paige , Fiascone, John M., Frantz, Ivan D. , Furey, Anne, Kurfiss, Anne, MacKinnon, Brenda L., McGowan, Elisabeth C. , Nylen, Ellen, Sibley, Cecelia, Chanlaw, Teresa , Devaskar, Uday, Garg, Meena, Geller, Rachel , Purdy, Isabell B., Arnell, Kathy, Demetrio, Clarence, Finer, Neil N., Fuller, Martha G. , Henderson, Christopher, Kaegi, David, Rasmussen, Maynard R., Rich, Wade , Vaucher, Yvonne E. , Wozniak, Paul R., Bernhardt, Janice, Bose, Carl , Bose, Gennie, Clark, Cynthia L., Warner, Diane, Wereszczak, Janice, Lacy, Conra Backstrom, Fuller, Janell, Hanson, Mary, Hartenberger, Carol H., Kuan, Elizabeth, Lowe, Jean, Ohls, Robin K. , Beauman, Sandra Sundquist , Thomson, Rebecca A., Watterberg, Kristi L. , Carlson, Martha, Christensen, Mary, Wiggins, Stephanie A., Baker, Shawna, Baserga, Mariana , Bird, Karie, Burnett, Jill, Christensen, Susan, Bledsoe, Laura Cole, Cunningham, Sean D. , Davis, Brandy, Elmont, Jennifer O., Faix, Roger G., Hall, Becky, Jensen, Erika R., Jensen, Jennifer J., Jordan, Jamie, Loertscher, Manndi C., Marchant, Trisha, Maxson, Earl, McGrath, Kandace M., Minton, Stephen D., Morshedzadeh, Galina, Osborne, Karen A., Parry, Dilys M. , Rau, Carrie A., Reich, Brixen A., Schaefer, Susan T., Sheffield, Mark J., Spencer, Cynthia, Steffen, Michael, Stout, Kelly, Stuart, Ashley L., Tice, Katherine, Weaver-Lewis, Kimberlee, Winter, Sarah , Woodbury, Kathryn D., Yoder, Bradley A. , Zanetti, Karen, Chiu, Korinne, Dillard, Robert G., Allred, Deborah Evans, Goldstein, Donald J., Halfond, Raquel, Jackson, Barbara G., O’Shea, T. Michael , Peters, Nancy, Peterson, Carroll, Waldrep, Ellen, Washburn, Lisa K. , Welch, Cherrie D. , Morris, Melissa Whalen, Hounshell, Gail, Kicklighter, Stephen D. , Rhodes-Ryan, Ginger, Abramczyk, Katherine, Agarwal, Prashant , Bajaj, Monika , Bara, Rebecca, Billian, Elizabeth, Chawla, Sanjay , Childs, Kirsten, Jesus, Lilia C. De, Driscoll, D., February, Melissa, Goldston, Laura A., Muran, Geraldine, Natarajan, Girija , Pappas, Athina, Prentice, Jeannette E., Shankaran, Seetha , Sood, Beena G. , White, Diane F., Woldt, Eunice, Butler, Christine G., Cervone, Patricia, Ehrenkranz, Richard A., Gettner, Patricia, Greisman, Sheila, Jacobs, Harris C., Konstantino, Monica, Poulsen, JoAnn, Romano, Elaine, Taft, Janet, Brumbaugh, Jane E. , Das, Abhik , Baack, Michelle L , Ambalavanan, Namasivayam , Carlo, Waldemar A. , Keszler, Martin , Oh, William, Watson, Victoria E. , Lakshminrusimha, Satyan , Hibbs, Anna Maria , Payne, Allison H. , Alexander, Barbara D. , Jobe, Alan Hall , Yolton, Kimberly , Brion, Luc P. , Chen, Lijun , Leon, Maria M. De, Miller, Nancy A., Rosenfeld, Charles R. , Sánchez, Pablo J. , Patel, Ravi M. , Dempsey, Allison G. , Green, Charles E. , Khan, Amir M , Lis, Anna E. , Martin, Karen , Dagle, John M. , Klein, Jonathan M. , Widness, John A. , Calejo, Maria, Fortney, Christine A. , Maitre, Nathalie L. , Nelin, Leif Daniel , Parikh, Nehal A. , Cook, Noah , Kirpalani, Haresh Murli , Mancini, Toni, Schmidt, Barbara Kristina , Vangala, Saritha, Kent, Alison , Sabaratnam, Premini , Bann, Carla , Crawford, Margaret M. , Gantz, Marie G. , Leblond, David, Newman, Jamie E. , Taylor, Heather Lee , Henderson, Christopher, Laughon, Matthew Maxwell , DuPont, Tara L. , Barks, John , Sarkar, Subrata , Parry, D. Melody, Spencer, Cynthia, Steffen, Michael, White, Donna, Johnson, Mary E. , Panaitescu, Bogdan , Williams, Joanne W.

Mayo Clinic

JAMA Network Open | December 8, 2022 | Volume: 5 | Issue: 12 | Pages: e2245826

10.1001/jamanetworkopen.2022.45826 | PMID 36480199 Get It

ImportanceLate-onset meningitis (LOM) has been associated with adverse neurodevelopmental outcomes in children born extremely preterm.ObjectiveTo report the incidence of LOM during birth hospitalization and neurodevelopmental outcomes at 18 to 26 months’ corrected age.Design, Setting, and ParticipantsThis cohort study is a secondary analysis of a multicenter prospective cohort of children born at 22 to 26 weeks’ gestation between 2003 and 2017 with follow-up from 2004 to 2021. The study was conducted at 25 Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network centers.ExposuresCulture-confirmed LOM.Main Outcomes and MeasuresIncidence and microbiology of LOM (2003-2017); lumbar puncture (LP) performance in late-onset sepsis (LOS) evaluations (2011-2017); composite outcome of death or neurodevelopmental impairment (NDI; 2004-2021).ResultsAmong 13 372 infants (median [IQR] gestational age, 25.4 [24.4-26.1] weeks; 6864 [51%] boys), LOM was diagnosed in 167 (1%); LOS without LOM in 4564 (34%); and neither LOS nor LOM in 8641 (65%). The observed incidence of LOM decreased from 2% (95% CI, 1%-3%) in 2003 to 0.4% (95% CI, 0.7%-1.0%) in 2017 (P < .001). LP performance in LOS evaluations decreased from 36% (95% CI, 33%-40%) in 2011 to 24% (95% CI, 21%-27%) in 2017 (P < .001). Among infants with culture-confirmed LOS, LP performance decreased from 58% (95% CI, 51%-65%) to 45% (95% CI, 38%-51%; P = .008). LP performance varied by center among all LOS evaluations (10%-59%, P < .001) and among those with culture-confirmed LOS (23%-79%, P < .001). LOM occurred in the absence of concurrent LOS in 27 of 167 cases (16%). The most common LOM isolates were coagulase-negative Staphylococcus (98 [59%]), Candida albicans (38 [23%]), and Escherichia coli (27 [16%]). Death or NDI occurred in 22 of 46 children (48%) with LOM due to coagulase-negative Staphylococcus, 43 of 67 (64%) due to all other bacterial pathogens, and 26 of 33 (79%) due to fungal pathogens. The adjusted relative risk of death or NDI was increased among children with LOM (aOR, 1.53; 95% CI, 1.04-2.25) and among those with LOS without LOM (aOR, 1.41; 95% CI, 1.29-1.54) compared with children with neither infection.Conclusions and RelevanceIn this cohort study, LP was performed with decreasing frequency, and the observed incidence of LOM also decreased. Both LOM and LOS were associated with increased risk of death or NDI; risk varied by LOM pathogen. The full association of LOM with outcomes of children born extremely preterm may be underestimated by current diagnostic practices.
Characterizing variability of electronic health record-driven phenotype definitions
Brandt, Pascal , Luo, Yuan , Pacheco, Jennifer A. , Walunas, Theresa L. , Håkonarson, Håkon , Liu, Cong , Walton, Nephi , Carrell, David , Crane, Paul K. , Chute, Christopher G. , Carroll, Robert J. , Denny, Joshua C. , Ramirez, Andrea H. , Wei, Wei‐Qi, Pathak, Jyoti , Wiley, Laura K. , Richesson, Rachel , Starren, Justin , Rasmussen, Luke V. , Brandt, Pascal S , Luo, Yuan , Pacheco, Jennifer A , Hakonarson, Hakon , Liu, Cong , Carrell, David S , Chute, Christopher G , Wiley, Laura K , Starren, Justin B , Rasmussen, Luke V , Denny, Joshua C , Richesson, Rachel L , Wei, Wei-Qi , Walunas, Theresa L , Kho, Abel , Hripcsak, George , Shang, Ning , Weng, Chunhua , Larson, Eric B. , Kullo, Iftikhar J. , Pathak, Jyoti

Mayo Clinic

Journal of the American Medical Informatics Association | December 7, 2022 | Volume: 30 | Issue: 3 | Pages: 427-437

10.1093/jamia/ocac235 | PMID 36474423 Get It

AbstractObjectiveThe aim of this study was to analyze a publicly available sample of rule-based phenotype definitions to characterize and evaluate the variability of logical constructs used.Materials and MethodsA sample of 33 preexisting phenotype definitions used in research that are represented using Fast Healthcare Interoperability Resources and Clinical Quality Language (CQL) was analyzed using automated analysis of the computable representation of the CQL libraries.ResultsMost of the phenotype definitions include narrative descriptions and flowcharts, while few provide pseudocode or executable artifacts. Most use 4 or fewer medical terminologies. The number of codes used ranges from 5 to 6865, and value sets from 1 to 19. We found that the most common expressions used were literal, data, and logical expressions. Aggregate and arithmetic expressions are the least common. Expression depth ranges from 4 to 27.DiscussionDespite the range of conditions, we found that all of the phenotype definitions consisted of logical criteria, representing both clinical and operational logic, and tabular data, consisting of codes from standard terminologies and keywords for natural language processing. The total number and variety of expressions are low, which may be to simplify implementation, or authors may limit complexity due to data availability constraints.ConclusionsThe phenotype definitions analyzed show significant variation in specific logical, arithmetic, and other operators but are all composed of the same high-level components, namely tabular data and logical expressions. A standard representation for phenotype definitions should support these formats and be modular to support localization and shared logic.
Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas
Fuentes, Harry E , Patel, Sandip Pravin , Mardiros, Armen, Han, Xu , Ng, Eric Wai-Choi , Go, William Y., Wong, Deborah Jean Lee, Sunwoo, John B. , Welch, John S. , Fuentes, Harry E , Xu, Han , Ng, Eric W , Kirtane, Kedar , John, Maie A. St.

Mayo Clinic

Journal of Clinical Medicine | December 7, 2022 | Volume: 11 | Issue: 24 | Pages: 7259

10.3390/jcm11247259 | PMID 36555876 Get It

Head and neck squamous cell cancers (HNSCCs) represent a diverse group of tumors emerging within different mucosal surfaces of the oral cavity, nasopharynx, oropharynx, larynx, and hypopharynx. HNSCCs share common clinical risk factors and genomic features, including smoking, alcohol, age, male sex, aneuploidy, and TP53 mutations. Viral initiating and contributing events are increasingly recognized in HNSCCs. While both Epstein–Barr Virus (EBV) and human papilloma virus (HPV) are observed, EBV is more frequently associated with nasopharyngeal cancers whereas HPV is associated with oropharyngeal cancers. HNSCCs are associated with high tumor mutational burden and loss of tumor suppressor gene function, especially in TP53 and X-linked genes. Multiple lines of evidence suggest that HNSCCs are subject to immunologic surveillance and immune-induced evolutionary pressure that correlate with negative clinical outcomes. This review will discuss genomic mechanisms related to immune-mediated pressures and propose prognostic and therapeutic implications of detectable immune escape mechanisms that drive tumorigenesis and disease progression.
The Combination of TIM3-Based Checkpoint Blockade and Oncolytic Virotherapy Regresses Established Solid Tumors
Gowan, Cody C., Bartee, Mee Y., Flores, Erica , Aksoy, Bülent Arman , Templeton, Conor W. , Baillie, Kati, Happe, Myroslawa, Bartee, Eric , Happe, Myra

Mayo Clinic

Journal of Immunotherapy | December 6, 2022 | Volume: 46 | Issue: 1 | Pages: 1-4

10.1097/cji.0000000000000444 | PMID 36472581 Get It

T-cell immunoglobulin and mucin domain 3 (TIM3) is emerging as a potential target for antibody-based checkpoint blockade. However, the efficacy of TIM3 blockade in combination with other treatment modalities, has not been extensively studied. In the current work we combined TIM3 blockade with myxoma virus-based oncolytic virotherapy (OV). Our results demonstrate that myxoma virus’s ability to initiate an immense antitumor immune response complements the ability of TIM3 blockade to shift the tumor microenvironment to a more proinflammatory state. As a result, the combination of TIM3 blockade and OV is able to completely eradicate established disease, while neither monotherapy is effective. These data represent the first demonstration that OV can enhance the efficacy of TIM3 blockade and suggest that this treatment may need to be incorporated into more aggressive, combinatorial regimens in order to fulfill its potential as an immunotherapeutic.
Abstract A003: Risks of ductal carcinoma in situ of the breast associated with pathogenic variants in cancer predisposition genes
Couch, Ronan E. , LaDuca, Holly , Goldgar, David E. , Pesaran, Tina , Dolinsky, Jill S. , Teras, Lauren R., Patel, Alpa V. , Ruddy, Kathryn J. , Vachon, Celine M. , Yao, Song, Huang, Huaizhi , Yadav, Siddhartha , Polley, Eric C. , Boddicker, Nicholas , Na, Jie , Gnanaolivu, Rohan , Hart, Steven N. , Palmer, Julie R. , Teras, Lauren R. , Olson, Janet E. , Vachon, Celine M. , Kraft, Peter , Yao, Song , Trentham‐Dietz, Amy , Nathanson, Katherine L. , Weitzel, Jeffrey N. , Domchek, Susan M. , Couch, Fergus J. , Hu, Chunling

Mayo Clinic

Cancer Prevention Research | December 1, 2022 | Volume: 15 | Issue: 12_Supplement_1 | Pages: A003-A003

10.1158/1940-6215.dcis22-a003 Get It

Abstract Introduction: The relationship between germline pathogenic variants (PVs) in cancer predisposition genes and ductal carcinoma in situ (DCIS) is not well established. The objective of this study is to determine the risks of DCIS and contralateral breast cancer among women with DCIS associated with germline PVs in cancer predisposition genes. Methods: Associations between pathogenic variants in 11 cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MSH6, PALB2, RAD51C, and RAD51D) and DCIS were determined in case control analyses of a population-based cohort of 3876 women with DCIS and age-matched unaffected women, and in a clinical cohort of 9887 DCIS cases undergoing clinical genetic testing at Ambry Genetics and unaffected reference controls. The incidence of contralateral breast cancer risk in BRCA1, BRCA2, and PALB2 PV carriers with DCIS was also evaluated in a time-to-event analysis. Results: The mean age at diagnosis of DCIS was 50 years in the clinical testing cohort and 59 years in the population-based cohort. The frequency of PVs in 11 predisposition genes among DCIS cases was 6.9% in the clinical testing cohort and 4.9% in the population-based cohort. PVs in ATM, BRCA1, BRCA2, CHEK2, MSH6, PALB2, and RAD51D were associated with significantly increased risks (Odds Ratio (OR) >2) of DCIS in the clinical testing cohort whereas only PVs in BRCA1, CHEK2, PALB2, and ATM were associated with significantly increased risks of DCIS in the population-based cohort. The cumulative incidence of contralateral breast cancer among BRCA1, BRCA2, and PALB2 PV carriers with DCIS was 11% in 5-years and 20% in 15-years. Conclusions: This study provides new insights into PVs that predispose to DCIS. In addition, it establishes an increased risk of contralateral breast cancer risk among women with DCIS who are carriers of PVs in BRCA1, BRCA2, or PALB2. These findings will guide surveillance and risk reducing strategies in germline PV carriers with DCIS. Citation Format: Huaizhi Huang, Ronan E. Couch, Holly LaDuca, Siddhartha Yadav, Eric C. Polley, Nicholas J. Boddicker, Jie Na, Rohan D. Gnanaolivu, David E. Goldgar, Tina Pesaran, Steven N. Hart, Jill S. Dolinsky, Julie R. Palmer, Lauren Teras, Alpa V. Patel, Kathryn J. Ruddy, Janet E. Olson, Celine M. Vachon, Peter Kraft, Song Yao, Amy Trentham-Dietz, Katherine L. Nathanson, Jeffrey N. Weitzel, Susan M. Domchek, Fergus J. Couch, Chunling Hu. Risks of ductal carcinoma in situ of the breast associated with pathogenic variants in cancer predisposition genes [abstract]. In: Proceedings of the AACR Special Conference on Rethinking DCIS: An Opportunity for Prevention?; 2022 Sep 8-11; Philadelphia, PA. Philadelphia (PA): AACR; Can Prev Res 2022;15(12 Suppl_1): Abstract nr A003.
Improved Prediction of Amyloid-β and Tau Burden Using Hippocampal Surface Multivariate Morphometry Statistics and Sparse Coding
Wu, Jianfeng , Initiative, for the Alzheimer’s Disease Neuroimaging, Zhu, Wenhui , Mallak, Negar Jalili , Leporé, Natasha , Reiman, Eric M. , Caselli, Richard J., Thompson, Paul M. , Thompson, Paul M , Initiative, for the Alzheimer’s Disease Neuroimaging, Su, Yi , Caselli, Richard J. , Chen, Kewei , Wang, Yalin

Mayo Clinic

Journal of Alzheimer's Disease | November 29, 2022 | Volume: 91 | Issue: 2 | Pages: 637-651

10.3233/jad-220812 | PMID 36463452 Get It

Background: Amyloid-β (Aβ) plaques and tau protein tangles in the brain are the defining ‘A’ and ‘T’ hallmarks of Alzheimer’s disease (AD), and together with structural atrophy detectable on brain magnetic resonance imaging (MRI) scans as one of the neurodegenerative (‘N’) biomarkers comprise the “ATN framework” of AD. Current methods to detect Aβ/tau pathology include cerebrospinal fluid (invasive), positron emission tomography (PET; costly and not widely available), and blood-based biomarkers (promising but mainly still in development). Objective: To develop a non-invasive and widely available structural MRI-based framework to quantitatively predict the amyloid and tau measurements. Methods: With MRI-based hippocampal multivariate morphometry statistics (MMS) features, we apply our Patch Analysis-based Surface Correntropy-induced Sparse coding and max-pooling (PASCS-MP) method combined with the ridge regression model to individual amyloid/tau measure prediction. Results: We evaluate our framework on amyloid PET/MRI and tau PET/MRI datasets from the Alzheimer’s Disease Neuroimaging Initiative. Each subject has one pair consisting of a PET image and MRI scan, collected at about the same time. Experimental results suggest that amyloid/tau measurements predicted with our PASCP-MP representations are closer to the real values than the measures derived from other approaches, such as hippocampal surface area, volume, and shape morphometry features based on spherical harmonics. Conclusion: The MMS-based PASCP-MP is an efficient tool that can bridge hippocampal atrophy with amyloid and tau pathology and thus help assess disease burden, progression, and treatment effects.